Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To expose attendees to the methodology and statistics of clinical trial development

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with NCIC Clinical Trials Group

1:30 – 1:35 pm  Welcome and Introduction  G. Goss/Y. Ung

Report from Study Chairs: Update on Current Trials:

1:35 – 1:45 pm  BRC.5:  A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (< 2cm) Peripheral Non-Small Cell Lung Cancer  G. Darling

1:45 – 1:55 pm  BR.31:  A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non Small Cell Lung Cancer  G. Goss


2:05 – 2:15 pm  BR.32:  A Randomized Phase II Study of Maintenance Therapy with Talazoparib or Placebo in Extensive Disease Small Cell Lung Cancer  N. Blais

IND Studies:

2:15 – 2:25 pm  IND.211:  A Randomized Phase II Study Of Reolysin in Patients with Previously Treated Advanced Or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy  D. Morris
2:25 – 2:35 pm  **IND.215:**
A Phase Ib Study Of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC who are Receiving Standard Chemotherapy Regimen

G. Nicholas

2:35 – 2:45 pm  **IND.219:**
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer

P. Bradbury

2:45 – 3:00 pm  BREAK

3:00 – 3:10 pm  Report from IND Committee

S. Laurie

3:10 – 3:20 pm  Report from Lung CSTB

M. Tsao

3:20 – 4:15 pm  New Concepts and Proposals

G. Goss/Y. Ung

4:15 pm  Summary and Close

G. Goss/Y. Ung